Table 4.
Clinical Features, Treatment, Complications, Mortality, and Duration of Hospitalization Among the Groups of Patients According to Severity
| Item | Mild Group n=66 (%) | Moderate Group n=134 (%) | Severe/Critical Group n= 60 (%) |
|---|---|---|---|
| Sex | |||
| Male | 28 (42.4) | 76 (56.7) | 40 (66.6) |
| Female | 38 (57.5) | 58 (43.2) | 20 (33.3) |
| Comorbidities | 8 (12.1) | 58 (43.3) | 38 (63.3) |
| Smoking | 4 (6) | 24 (17.9) | 16 (26.7) |
| Symptomatic therapy | 54 (81.8) | 134 (100) | 60 (100) |
| Azithromycin therapy | 36 (54.5) | 98 (73.1) | 40 (66.6) |
| Hydroxychloroquine | 12 (18.2) | 24 (17.9) | 10 (16.6) |
| Favipiravir | 8 (12.1) | 6 (4.5) | 0 |
| Anticoagulants | 0 | 12 (8.9) | 8 (13.3) |
| O2 therapy | 0 | 2 (1.5) | 52 (86.7) |
| Mechanical ventilation | 0 | 0 | 8 (13.3) |
| Complications | |||
| ARDS | 0 | 0 | 12 (20) |
| Acute renal injury | 0 | 14 (10.4) | 4 (6.7) |
| ARDS and renal injury | 0 | 0 | 8 (13.3) |
| Bacterial/fungal co-infection | 0 | 8 (6) | 20 (33.3) |
| Deaths | 0 | 0 | 24 (40) |
| Range of duration of hospitalization | 5–29 days | 7–33 days | 1–10 days |